Antiamnesic use of pteridine derivatives

• US 5,047,405 A
• Filed: 02/27/1990
• Issued: 09/10/1991
• Est. Priority Date: 05/14/1987
• Status: Expired due to Fees

• Current Assignee: Knoll Farma S.p.A.
• Original Assignee: BIO Research S.p.A.
• Inventors: Gennari, Federico
• Primary Examiner(s): Shah, Mukund J.
• Assistant Examiner(s): Grumbling, Matthew V.
• Application Number:
  US07/488,438
• Time in Patent Office: 560 Days
• Field of Search: 544/257, 514/249
• US Class Current: 514/249
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07D 475/00 Heterocyclic compounds containing pteridine ring systems
• CPC Class Codes: C07D 475/02 with an oxygen atom directly attached in position 4
• CPC Class Codes: C07D 475/04 with a nitrogen atom directly attached in position 2
• CPC Class Codes: C07D 475/06 with a nitrogen atom directly attached in position 4
• CPC Class Codes: C07D 475/08 with a nitrogen atom directly attached in position 2

Abstract

Pteridines of general formula (I): ##STR1## in which Y and Z, which can be identical or different, are hydrogen, OH or NH₂, and X₁ and X₂, which can be identical or different, are hydrogen, OH, C₁ -C₄ alkyl, phenyl, hydroxymethyl or carboxyl, for the preparation of pharmaceutical compositions for treating cognitive pathologies characterized by memory and vigilance disturbances, such as senile dementia of Alzheimer type, multiinfarctual dementia, metabolic encephalopathies, Korsakoff'"'"'s syndrome, and the consequences of the abuse of certain therapies such as anxiolytic and neuroleptic.

Claims

1. A therapeutic process for treating memory and vigilance disturbance nature cognitive pathologies including Alzheimer-type senile dementia, multiinfarctual dementia, metabolic encephalopathies, Korsakoff'"'"'s syndrome, and the consequences of the abuse of anxiolytic and neuroleptic therapies, said process comprising

administering to a patient in need thereof a therapeutically effective amount of a pteridine of the formula ##STR3## wherein Y and Z can be the same or different and are H, OH, or NH₂ and X₁ and X₂ can be the same or different and are OH, C₁ -C₄ alkyl, phenyl, hydroxymethyl, or carboxyl.

2. The process of claim 1, wherein said pteridine is administered by injection.

3. The process of claim 1, wherein said pteridine is administered orally.

4. The process of claim 3, wherein said pteridine is administered in the form of a tablet, pill, capsule, sachet, or syrup.